

"Hepatitis C: The beginning of the end - key elements for successful European and national strategies to eliminate HCV in Europe"

## **PROGRAMME**

| Timing                   | Programme item  |
|--------------------------|---|
| 13:15-<br>13:20<br>(5')  | Welcome address Chairs: Prof. Michael P. Manns – Co-Chair HepBC PPA & Hannover Medical School, Prof. Angelos Hatzakis – Co-Chair HepBC PPA & University of Athens   |
|                          | 13:15-13:20 Welcome to event & scene-setting – Prof. Angelos Hatzakis   |
| 13:20-<br>13:35<br>(15') | Keynote address Chair: Prof. Michael Manns – Co-Chair HepBC PPA & Hannover Medical School Dr. Vytenis Andriukaitis – European Commissioner for Health   |
| 13:35-<br>13:55<br>(20') | Introductory remarks – Why HCV must and can be eliminated in Europe Chairs: Prof. Michael P. Manns – Co-Chair HepBC PPA & Hannover Medical School, Prof. Angelos Hatzakis – Co-Chair HepBC PPA & University of Athens |
|                          | 13:35-13:40 Welcome & introductory remarks – Dr. Cristian-Silviu Buşoi, Member of the European Parliament and Co-Chair of the Friends of the Liver MEP Group  |
|                          | 13:40-13:45 Introductory comments – Dr. Tatjana Reic, President, European Liver Patients Association  |
|                          | 13:45-13:50 Introductory comments – Eberhard Schatz, Director Correlation Network   |
|                          | 13:50-13:55 Introductory comments – Prof. Helena Cortez Pinto, EU Policy Councillor Elect, European Association for the Study of the Liver  |
| 13:55-<br>15:05          | Session 1: A successful elimination strategy for HCV in Europe: current challenges and criteria for success   |
| (70')                    | Chairs: Prof. Pierre van Damme – Viral Hepatitis Prevention Board, Prof. Markus Peck-Radosavljevic – University of Klagenfurt   |
|                          | 13:55-14:05 The Burden of HCV in European Union – Dr. Homie Razavi, Center for Disease Analysis   |
|                          | 14:05-14:15 Elimination of hepatitis and the first WHO Global Hepatitis Strategy – Dr. Stephan Wiktor, World Health Organisation  |
|                          | 14:15-14:25 The cost of HCV elimination – Prof. Jagpreet Chhatwal, Massachusetts General Hospital and Professor at Harvard Medical School   |
|                          | 14:25-14:35 Key elements of a successful elimination strategy from a patient perspective – Achim Kautz, European Liver Patients Association   |
|                          | 14:35-14:45 The public health challenges that need to be overcome to eliminate HCV – John F. Ryan, European Commission  |
|                          | 14:45-15:05 Panel discussion moderated by Prof. Manuel Carballo – International Centre for Migration, Health and Development  |

| 15:35 (30')  15:35- 16:55 (80')  Session 2: Practical steps to eliminate HCV at national/local level (examples of existin practice) Chairs: Prof. Massimo Colombo – University of Milan, Prof. Nurdan Tözün – Acibadem U. 15:35-16:35  - Prevention – Dr. Ingo Michels, Federal Ministry of Health, Germany - Screening – Dr. Yazdan Yazdanpanah, Hôpital Bichat-Claude Bernard Paris, Fra - Linkage to care – Prof. David Goldberg, Health Protection Scotland, Scotland - Harm reduction – Dr. Luís Mendão, Portuguese Activist Group for HIV/AIDS Troportugal - Access to treatment – Dr. Ricardo Baptista Leite, Catholic University, Portugal - Political will – Dr. Freke Zuure, Department of Infectious Diseases Research & Netherlands  16:35–16:55 Panel discussion moderated by Prof. Massimo Colombo – University of Milan, Prof. Milan, Prof. Massimo Colombo – University of Milan, Prof. Milan, Prof. Massimo Colombo – University of Milan, Prof. |                |
|--|----------------|
| 15:35- 16:55 (80')  Session 2: Practical steps to eliminate HCV at national/local level (examples of existin practice) Chairs: Prof. Massimo Colombo — University of Milan, Prof. Nurdan Tözün — Acibadem U 15:35-16:35  Prevention — Dr. Ingo Michels, Federal Ministry of Health, Germany Screening — Dr. Yazdan Yazdanpanah, Hôpital Bichat-Claude Bernard Paris, Fra Linkage to care — Prof. David Goldberg, Health Protection Scotland, Scotland Harm reduction — Dr. Luís Mendão, Portuguese Activist Group for HIV/AIDS Tra Portugal Access to treatment — Dr. Ricardo Baptista Leite, Catholic University, Portugal Political will — Dr. Freke Zuure, Department of Infectious Diseases Research & Netherlands  16:35—16:55 Panel discussion moderated by Prof. Massimo Colombo — University of Milan, Prof. Session 3: The role of EU and national policies in supporting the elimination of viral hours of the Europe Chairs: Prof. Heiner Wedemeyer — Hannover Medical School, Prof. George Papatheodo University   |                |
| 16:55  |                |
| Chairs: Prof. Massimo Colombo – University of Milan, Prof. Nurdan Tözün – Acibadem U 15:35-16:35  - Prevention – Dr. Ingo Michels, Federal Ministry of Health, Germany - Screening – Dr. Yazdan Yazdanpanah, Hôpital Bichat-Claude Bernard Paris, Fra - Linkage to care – Prof. David Goldberg, Health Protection Scotland, Scotland - Harm reduction – Dr. Luís Mendão, Portuguese Activist Group for HIV/AIDS Troportugal - Access to treatment – Dr. Ricardo Baptista Leite, Catholic University, Portugal - Political will – Dr. Freke Zuure, Department of Infectious Diseases Research & Netherlands  16:35–16:55 Panel discussion moderated by Prof. Massimo Colombo – University of Mi  16:55- 17:55 (60')  Session 3: The role of EU and national policies in supporting the elimination of viral hoursests of the prof. Heiner Wedemeyer – Hannover Medical School, Prof. George Papatheodo University   | Jniversity     |
| 15:35-16:35  - Prevention – Dr. Ingo Michels, Federal Ministry of Health, Germany - Screening – Dr. Yazdan Yazdanpanah, Hôpital Bichat-Claude Bernard Paris, Fra - Linkage to care – Prof. David Goldberg, Health Protection Scotland, Scotland - Harm reduction – Dr. Luís Mendão, Portuguese Activist Group for HIV/AIDS Tra - Portugal - Access to treatment – Dr. Ricardo Baptista Leite, Catholic University, Portugal - Political will – Dr. Freke Zuure, Department of Infectious Diseases Research & Netherlands  16:35–16:55 Panel discussion moderated by Prof. Massimo Colombo – University of Mi  16:55- 17:55  (60')  Session 3: The role of EU and national policies in supporting the elimination of viral had be supposed to the prof. Heiner Wedemeyer – Hannover Medical School, Prof. George Papatheodo University  | University     |
| - Prevention – Dr. Ingo Michels, Federal Ministry of Health, Germany - Screening – Dr. Yazdan Yazdanpanah, Hôpital Bichat-Claude Bernard Paris, Fra - Linkage to care – Prof. David Goldberg, Health Protection Scotland, Scotland - Harm reduction – Dr. Luís Mendão, Portuguese Activist Group for HIV/AIDS Transportugal - Access to treatment – Dr. Ricardo Baptista Leite, Catholic University, Portugal - Political will – Dr. Freke Zuure, Department of Infectious Diseases Research & Netherlands  16:35–16:55 Panel discussion moderated by Prof. Massimo Colombo – University of Mi  16:55- 17:55 (60')  Session 3: The role of EU and national policies in supporting the elimination of viral health is comparable to the comparable of the com |                |
| - Screening – Dr. Yazdan Yazdanpanah, Hôpital Bichat-Claude Bernard Paris, Fra - Linkage to care – Prof. David Goldberg, Health Protection Scotland, Scotland - Harm reduction – Dr. Luís Mendão, Portuguese Activist Group for HIV/AIDS Tro Portugal - Access to treatment – Dr. Ricardo Baptista Leite, Catholic University, Portugal - Political will – Dr. Freke Zuure, Department of Infectious Diseases Research & Netherlands  16:35–16:55 Panel discussion moderated by Prof. Massimo Colombo – University of Mi  16:55- 17:55 (60')  Session 3: The role of EU and national policies in supporting the elimination of viral hours of the Europe Chairs: Prof. Heiner Wedemeyer – Hannover Medical School, Prof. George Papatheodo University  |                |
| 16:35–16:55 Panel discussion moderated by Prof. Massimo Colombo – University of Mi  16:55- 17:55 (60')  Session 3: The role of EU and national policies in supporting the elimination of viral he Europe Chairs: Prof. Heiner Wedemeyer – Hannover Medical School, Prof. George Papatheodo University  | eatment,       |
| 17:55 (60')  Europe Chairs: Prof. Heiner Wedemeyer – Hannover Medical School, Prof. George Papatheodo University   | lan            |
| (60') Chairs: Prof. Heiner Wedemeyer – Hannover Medical School, Prof. George Papatheodo University   | epatitis in    |
| University   |                |
| 46 55 47 05  | ridis – Athens |
| 16:55-17:35  - Action plan for the prevention and control of viral hepatitis in the WHO Europe  2016–2021 – Dr. Antons Mozalevskis, WHO Europe   | ean Region     |
| <ul> <li>ECDC's priorities for supporting EU/EEA countries in their plans to eliminate He<br/>Duffell, European Centre for Disease Prevention and Control</li> </ul>   | CV – Dr. Erika |
| <ul> <li>HCV among people who inject drugs: harm reduction, screening and treatmen<br/>successful strategy – Alexis Goosdeel, European Monitoring Centre for Drugs a<br/>Addiction</li> </ul>  |                |
| <ul> <li>The role of national and EU policies from the Greek perspective – Dr. Ioannis B<br/>Ministry of Health, Greece</li> </ul>   | Baskozos,      |
| 17:35-17:55 Panel debate moderated by Charles Gore – World Hepatitis Alliance & Co-PPA   | Chair HepBC    |
| 17:55- Official presentation of the HCV Elimination Manifesto  |                |
| 18:15 Chair: Prof. Antonio Craxi – University of Palermo   |                |
| Presentation by: Prof. Jeffrey Lazarus – Centre for Health and Infectious Disease Resear Thursz – Imperial College   | ch, Prof. Mark |
| 18:15- Wrap up and concluding remarks  |                |
| 18:25 (10') Prof. Michael P. Manns – Co-Chair HepBC PPA & Hannover Medical School  |                |